Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT01470274
First received: November 9, 2011
Last updated: April 4, 2012
Last verified: April 2012
  Purpose

The primary objective is to establish the safety of the CO-rebreathing method for measuring total blood and plasma volume in CAD patients. The working hypothesis is that the CO-rebreathing method is safe in use with coronary artery disease patients and that it does not cause myocardial ischemia or cardiovascular damage.


Condition
Cardiovascular Disease
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Biospecimen Retention:   Samples Without DNA

Blood samples


Enrollment: 18
Study Start Date: November 2011
Study Completion Date: February 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Stable, optimally medicated coronary artery disease and COPD patients with LVEF ≥ 0.40 will be recruited

Criteria

Inclusion Criteria:

  • Stable coronary artery disease
  • Stable COPD
  • Optimal medication

Exclusion Criteria:

  • Unstable disease
  • co-morbidities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01470274

Locations
Norway
Norwegian University of Science and Technology
Trondheim, Norway, 7489
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Trine Karlsen, PhD Norwegian University of Science and Technology
  More Information

No publications provided

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT01470274     History of Changes
Other Study ID Numbers: 2011/1792
Study First Received: November 9, 2011
Last Updated: April 4, 2012
Health Authority: Norway: Regional Ethics Commitee

Keywords provided by Norwegian University of Science and Technology:
Blood volume
CO-rebreathing
COPD
CVD

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Heart Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014